China imposes an immediate ban on exports of dual-use items—goods with potential military applications, including certain rare earth elements—to Japan on January 6, 2026. Beijing cites provocative comments by Japanese Prime Minister Sanae Takaichi on Taiwan as the trigger, escalating tensions between the two Asian powers.
Trigger Takaichi’s Taiwan Statement
Takaichi’s late 2025 remarks describe a Chinese attack on Taiwan as an “existential threat” to Japan. China condemns this as crude interference in internal affairs, violating the one-China principle. The commerce ministry frames the ban as a defensive measure against Japan’s military buildup.
The restrictions cover over 1,100 items on China’s dual-use list, such as rare earths critical for drones, chips, and advanced weapons. Exports for military end-uses or enhancing Japan’s capabilities prohibit outright. Civilian uses may still allow, but scrutiny intensifies.
Impact on Japan and Global Supply Chains
Japan relies heavily on China for rare earths (over 60% of imports). Industries like automotive, electronics, and defense face potential disruptions. Tokyo accelerates diversification efforts, including stockpiling and alternative sourcing from Australia and Vietnam.
No immediate export drop appears in late 2025 data, but the ban’s enforcement could ripple through supply chains.
This retaliation occurs amid heightened regional frictions, including US alliances and Japan’s increased defense spending. It weaponizes China’s dominance in critical minerals, highlighting vulnerabilities in global tech and military production.
Mercedes-Benz to accelerate localisation as China revenue slump hits 2025 profits 
Trump administration signs trade deal to lower Taiwan’s tariff barriers 
TSMC invests $250 billion, Taiwan tariffs drop to 15% 
China’s DeepSeek Upgrades Chatbot with Advanced ‘Interleaved Thinking’ Feature Amid Next Model Buzz 
North Korea Fires Ballistic Missiles Hours Before South Korean President’s China Visit 
MindRank Advances China’s First AI-Assisted Drug to Phase 3 Trials, Slashes R&D Costs by 60%